mTOR is a very promising pathway because it’s so central in growth, migration, and survival of bladder cancer cells, explained Donna Hansel, MD, PhD, chief, anatomic pathology, UC San Diego.
mTOR is a very promising pathway because it’s so central in growth, migration, and survival of bladder cancer cells, explained Donna Hansel, MD, PhD, chief, anatomic pathology, UC San Diego.
Transcript
Advanced bladder has limited therapeutic options when conventional therapy has failed. How does your lab approach the identification of targetable pathways for advanced bladder cancer?
So, my lab focuses primarily on the mammalian target of rapamycin, or mTOR, signaling pathway, and we know from The Cancer Genome Atlas (TCGA) data that was produced that a very large number of bladder cancers, advanced bladder cancers, have some sort of alteration that affects signaling through the mTOR pathway. Despite some initial trials looking at mTOR inhibition, we feel it’s a very promising pathway because it’s so central in growth, in migration, in survival of bladder cancer cells, that we’ve continued to study it.
What we’ve done is to focus on 2 aspects of mTOR signaling and to try and understand what happens downstream from it, because it’s very likely that if we understand more about the mTOR pathway, that includes both mTORC1 and mTORC2, we’ll be able to better define potentially more actionable targets that we could find downstream.
So, for example, focusing on mTORC2, which has been a big passion of my lab members, we have now identified approximately 50 downstream targets, novel targets, that do affect migration, and do affect invasion. In bladder cancer, it’s critical to understand that invasive pathway that leads to higher local stages, but it’s also important to understand how invasion and interaction with the endothelial cells then leads to metastasis. We’re finding more and more information studying mTORC2 that indeed there are a number of very unique regulators downstream that affect both of these pathways, and all of which are quite actionable.
The Pivotal Role of Payers in Improving Health Equity, Maternal Health Care in the US
March 26th 2024A presentation at the Greater Philadelphia Business Coalition on Health's 2024 Women’s Health Summit discussed how payers, including employers and public entities, can strategically influence health care purchasing to prioritize maternal health and equity.
Read More
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Dupilumab Considered Safe, Effective Treatment for Adolescent, Adult Patients With AD
March 20th 2024These posters both used the GLOBOSTAD study, which demonstrated through patient and physician assessments that dupilumab is a safe and effective treatment for adolescent and adult patients with atopic dermatitis (AD).
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Racial Variations in Cardiovascular Outcomes Found in Hidradenitis Suppurativa Study
March 19th 2024Based on the findings, investigators acknowledged the critical need to consider racial differences when assessing patients with hidradenitis suppurativa. Health care providers should be vigilant in addressing cardiovascular risk factors in this population, recognizing and addressing racial disparities that may impact disease management.
Read More